AEROLATE JR
Clinical safety rating
cautionComprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
| Metabolism | Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations. |
| Excretion | Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%. |
| Half-life | Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold. |
| Protein binding | Approximately 70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding. |
| Bioavailability | Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism. |
| Onset of Action | Oral administration: Onset of bronchodilation occurs within 30 minutes, with peak effect at 2-4 hours. |
| Duration of Action | Duration of bronchodilation: 8-12 hours, allowing twice-daily dosing. Duration may be shorter in acute exacerbations or with suboptimal dosing. |
| Molecular Weight | 576.7 |
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No adjustment required as drug is primarily hepatically metabolized. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult. |
| Geriatric use | No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at therapeutic doses. Avoid in first trimester unless benefit outweighs risk. |
| 2nd trimester | Use with caution; may cause fetal tachycardia or hypoglycemia if used near term. Monitor fetal heart rate. |
| 3rd trimester | Avoid in late pregnancy (especially after 28 weeks) due to risk of premature labor, fetal tachycardia, and neonatal hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).
| Placental transfer | Crosses placenta; degree of transfer is estimated to be moderate based on molecular weight and lipid solubility. |
| Breastfeeding | Excreted into breast milk in small amounts; potential for infant beta-2 agonist effects (tachycardia, irritability). Use with caution, especially in preterm infants. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, serum potassium. Fetal: heart rate monitoring; consider ultrasonography for fetal growth restriction with prolonged use. |
| Fertility Effects | No known impairment in human fertility. Animal studies show no adverse effects on fertility at clinically relevant doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to the drug or any componentCardiac arrhythmias associated with tachycardiaHypokalemia (uncorrected)
| Precautions | Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism. |
| Food/Dietary | High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine. |
| Clinical Pearls | AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/mL). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer. |
| Patient Advice | Take exactly as prescribed; do not change dose without consulting doctor. · Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects. · Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures. · Do not smoke or abruptly stop smoking; notify doctor if smoking habits change. · Keep regular appointments for blood level monitoring. |
Loading safety data…